Masayoshi Inoue1, Meinoshin Okumura2, Noriyoshi Sawabata2, Etsuo Miyaoka3, Hisao Asamura4, Ichiro Yoshino5, Hirohito Tada6, Yoshitaka Fujii7, Yoichi Nakanishi8, Kenji Eguchi9, Masaki Mori10, Hideo Kobayashi11, Kohei Yokoi12. 1. Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. Electronic address: mi@thoracic.med.osaka-u.ac.jp. 2. Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. 3. Department of Mathematics, Science University of Tokyo, Tokyo, Japan. 4. Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan. 5. Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan. 6. Division of General Thoracic Surgery, Osaka City General Hospital, Osaka, Japan. 7. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Science and Medical School, Nagoya, Japan. 8. Department of Clinical Medicine, Research Institute for Diseases of the Chest, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. 9. Department of Medical Oncology, Teikyo University School of Medicine, Tokyo, Japan. 10. Department of Pulmonary Medicine, Sapporo-Kosei General Hospital, Hokkaido, Japan. 11. Division of Respiratory Disease, National Defense Medical College, Tokorozawa, Japan. 12. Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Abstract
OBJECTIVE: The clinicopathological characteristics and surgical results of young lung cancer patients were investigated. MATERIALS AND METHODS: Seven hundred and four (6.0%) patients with lung cancer, aged up to 50 years, were enrolled from among the 11,663 patients registered in the Japanese Lung Cancer Registry Study 2004, and their clinical data were compared with those of 10,959 patients older than 50 years. This epidemiological study is based on the single year registration of surgically treated patients in the major institutes in Japan. RESULTS: The 5-year overall survival rate (5Y-OS) and the 5-year lung cancer-related survival rate was 79.2%/69.0% (p<0.001) and 81.3%/76.6% (p=0.005) in the young/old groups, respectively. In the young/old groups, lobectomy and pneumonectomy was performed in 76.9%/78.0% and 5.7%/3.2%, respectively; adjuvant therapies were given preoperatively in 10.4%/4.7% (p<0.001) and postoperatively in 31.4%/24.5% (p<0.001). The proportions of patients with p-stage IIIA (18.2%) and adenocarcinoma histology (78.7%) were higher in the young group. The 5Y-OS was 94.8%/86.2% for p-stage IA (p<0.001), 87.0%/73.2% for p-stage IB (p=0.001), 61.0%/61.6% for p-stage IIA (p=0.595), 71.0%/48.4% for p-stage IIB (p=0.003), 49.6%/39.4% for p-stage IIIA (p=0.020), and 80.0%/24.8% for p-stage IIIB (p=0.012); it was 83.5%/80.7% for females (p=0.106) and 75.1%/62.3% for males (p<0.001) in the young/old groups. The postoperative survival was significantly better with all operative procedures in the young group. The 5Y-OS after recurrence was 17.9%/13.4% in the young/old groups (p=0.016). In the young group, the 5Y-OS was better in females (83.5%) than in males (75.1%, p=0.002), and for patients with adenocarcinoma (80.3%) than for those with squamous cell carcinoma (68.5%, p=0.013). Age up to 50 years was identified as an independent better prognostic factor on multivariate analysis. CONCLUSIONS: The postoperative survival in lung cancer patients aged up to 50 years was better than that in patients older than 50 years.
OBJECTIVE: The clinicopathological characteristics and surgical results of young lung cancerpatients were investigated. MATERIALS AND METHODS: Seven hundred and four (6.0%) patients with lung cancer, aged up to 50 years, were enrolled from among the 11,663 patients registered in the Japanese Lung Cancer Registry Study 2004, and their clinical data were compared with those of 10,959 patients older than 50 years. This epidemiological study is based on the single year registration of surgically treated patients in the major institutes in Japan. RESULTS: The 5-year overall survival rate (5Y-OS) and the 5-year lung cancer-related survival rate was 79.2%/69.0% (p<0.001) and 81.3%/76.6% (p=0.005) in the young/old groups, respectively. In the young/old groups, lobectomy and pneumonectomy was performed in 76.9%/78.0% and 5.7%/3.2%, respectively; adjuvant therapies were given preoperatively in 10.4%/4.7% (p<0.001) and postoperatively in 31.4%/24.5% (p<0.001). The proportions of patients with p-stage IIIA (18.2%) and adenocarcinoma histology (78.7%) were higher in the young group. The 5Y-OS was 94.8%/86.2% for p-stage IA (p<0.001), 87.0%/73.2% for p-stage IB (p=0.001), 61.0%/61.6% for p-stage IIA (p=0.595), 71.0%/48.4% for p-stage IIB (p=0.003), 49.6%/39.4% for p-stage IIIA (p=0.020), and 80.0%/24.8% for p-stage IIIB (p=0.012); it was 83.5%/80.7% for females (p=0.106) and 75.1%/62.3% for males (p<0.001) in the young/old groups. The postoperative survival was significantly better with all operative procedures in the young group. The 5Y-OS after recurrence was 17.9%/13.4% in the young/old groups (p=0.016). In the young group, the 5Y-OS was better in females (83.5%) than in males (75.1%, p=0.002), and for patients with adenocarcinoma (80.3%) than for those with squamous cell carcinoma (68.5%, p=0.013). Age up to 50 years was identified as an independent better prognostic factor on multivariate analysis. CONCLUSIONS: The postoperative survival in lung cancerpatients aged up to 50 years was better than that in patients older than 50 years.
Authors: Wooil Kim; Ho Yun Lee; Sin-Ho Jung; Min-Ah Woo; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jae Ill Zo; Young Mog Shim; Joungho Han; Ji Yun Jeong; Joon Young Choi; Kyung Soo Lee Journal: Oncotarget Date: 2017-05-09